Centessa Pharmaceuticals PLC ADR

NASDAQ CNTA

Data sourced from

and

Download Data

Centessa Pharmaceuticals PLC ADR Cash Taxes 5 year CAGR for the quarter ending March 31, 2024

Centessa Pharmaceuticals PLC ADR Cash Taxes 5 year CAGR is NA for the quarter ending March 31, 2024. Cash taxes represent the total amount of cash paid for income taxes, including both current and deferred taxes. It is calculated by summing the income tax provision and any non-cash tax-related items. This metric provides insight into the company's cash outflows related to taxes, which can impact its overall cash position and liquidity. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Centessa Pharmaceuticals PLC ADR Cash Taxes for the quarter ending March 31, 2023 was USD 1.65 M, a 42.41% change year over year.
Centessa Pharmaceuticals PLC ADR Cash Taxes for the quarter ending March 31, 2022 was USD 1.16 M.

NASDAQ: CNTA

Centessa Pharmaceuticals PLC ADR

CEO	Dr. Saurabh Saha M.D., Ph.D.
IPO Date	May 28, 2021
Location	United Kingdom
Headquarters	1 Ashley Road, Altrincham, United Kingdom, WA14 2DT
Employees	77
Sector	Healthcare
Industry	Biotechnology

Description

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Key trends